Market revenue in 2023 | USD 20,891.0 million |
Market revenue in 2030 | USD 51,954.2 million |
Growth rate | 13.9% (CAGR from 2023 to 2030) |
Largest segment | Interferons |
Fastest growing segment | Growth Hormones |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
Interferons was the largest segment with a revenue share of 21.46% in 2023. Horizon Databook has segmented the Global recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
Can be influenced by increasing R&D activities, facility expansions, and growing disease burden. Analyzing market influencers involves innovation, acquisitions, and presence of pharmaceutical and biotech firms.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account